OptimizeRx's (OPRX) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• OptimizeRx's stock received a "Sell (D-)" rating from Weiss Ratings, indicating concerns about the company's performance.
• Despite the negative rating, eight analysts have assigned a Buy rating to OptimizeRx, with an average price target of $11.81.
• Insider trading activity showed a 20.10% decrease in ownership for Director Patrick D. Spangler after selling shares, signaling potential lack of confidence in the stock's future performance.

OptimizeRx (NASDAQ:OPRX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by stock analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Other equities analysts have also recently issued research reports about the company. Roth Capital restated a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. Zacks Research upgraded OptimizeRx from a "hold" rating to a "strong-buy" rating in a report on Friday, September 5th. Stifel Nicolaus lifted their price target on OptimizeRx from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, JMP Securities lifted their price target on OptimizeRx from $14.00 to $20.00 and gave the stock a "market outperform" rating in a report on Monday, August 11th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $11.81.

OptimizeRx Stock Performance

OPRX opened at $18.24 on Wednesday. The business's 50-day moving average price is $17.24 and its two-hundred day moving average price is $13.36. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $20.69. The company has a market capitalization of $338.72 million, a price-to-earnings ratio of -33.78 and a beta of 1.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57.

Insiders Place Their Bets

In other OptimizeRx news, Director Patrick D. Spangler sold 11,120 shares of the company's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the sale, the director owned 44,215 shares of the company's stock, valued at approximately $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen L. Silvestro sold 1,620 shares of the company's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $18.75, for a total transaction of $30,375.00. Following the transaction, the chief executive officer owned 188,916 shares in the company, valued at $3,542,175. This represents a 0.85% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On OptimizeRx

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Manatuck Hill Partners LLC grew its position in OptimizeRx by 139.5% in the 2nd quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company's stock worth $6,142,000 after purchasing an additional 265,000 shares in the last quarter. Massar Capital Management LP bought a new position in OptimizeRx in the 2nd quarter worth approximately $297,000. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company's stock worth $55,000 after buying an additional 2,215 shares during the period. Balyasny Asset Management L.P. purchased a new stake in OptimizeRx in the 2nd quarter worth approximately $2,111,000. Finally, Ameriprise Financial Inc. purchased a new stake in OptimizeRx in the 2nd quarter worth approximately $943,000. Institutional investors and hedge funds own 76.47% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.